Into The Neural Crystal Ball: Forecasting The Future Of CNS Drug Development

Beatrice Setnik, Ph.D., Chief Scientific Officer, Altasciences, leads a forward-looking discussion on the evolution of central nervous system (CNS) drug development, where scientific innovation, regulatory progress, and advanced technologies are converging to reshape the therapeutic landscape. As the global CNS therapeutics market is projected to more than double over the next decade, renewed momentum is being driven by rising disease prevalence, increased investment, and breakthroughs across small molecules, biologics, psychedelics, medical devices, and artificial intelligence (AI)-enabled discovery.

This session provides a comprehensive overview of the trends, challenges, and opportunities defining this rapidly evolving field. Despite persistent hurdles — such as complex brain biology, high placebo response rates, and historically low clinical success — emerging approaches in precision medicine, biomarker development, and digital health are transforming how CNS therapies are developed and evaluated. Viewers can explore how these innovations are improving clinical trial design, accelerating timelines, and enhancing patient outcomes.

The presentation also highlights how Altasciences integrates operational expertise with technological advancements to support the growing pipeline of CNS compounds. Designed for pharmaceutical and biotech professionals, scientists, clinicians, and regulatory specialists, this session offers valuable insights into the future of CNS drug development.